Global Microbiome Sequencing Market, By Sequencing Technology (High-Throughput Sequencing, Sanger Sequencing, SBL, RNA Sequencing, SBS, Third-Generation Sequencing, Whole Genome Sequencing, Targeted Gene Sequencing, Shotgun Sequencing, Others), Component (Reagents & Kits, Instruments), Targeted Disease (CNS Diseases, Gastrointestinal Diseases, Oncology, Infectious Diseases, Others), Application (Personalized Medicine, Genetic Screening, Therapeutic, Drug & Biomarker Discovery, Disease Diagnosis Research, Others), Research Type (Outsourced, In-House), End-User (Pharmaceutical & Biotechnology, Academic Centers & Research Institutes, CROs, Others), Laboratory Type (Dry Lab, Wet Lab) – Industry Trends and Forecast to 2030.
Microbiome Sequencing Market Analysis and Size
Rise in the adoption of genomic research methods coupled with the widening areas of application for microbiome sequencing technology are the major factors that will enhance the growth of global microbiome sequencing market. Moreover, growing demand for next generation services, low cost related with the NGS technology which will also increase the adoption rate are the driving factors accelerating the growth of the global microbiome sequencing market. Increasing investment expenditure being incurred on advancing and utilization of microbiome research will uplift the growth of the market.
Data Bridge Market Research analyses that the global microbiome sequencing market which was USD 1204.15 million in 2022, is expected to reach USD 5875.40 million by 2030, and is expected to undergo a CAGR of 18.7% during the forecast period 2023-2030. High-throughput sequencing dominates the sequencing technology segment of the global microbiome sequencing market owing to the high demand of this type of analysers. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Microbiome Sequencing Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Sequencing Technology (High-Throughput Sequencing, Sanger Sequencing, SBL, RNA Sequencing, SBS, Third-Generation Sequencing, Whole Genome Sequencing, Targeted Gene Sequencing, Shotgun Sequencing, Others), Component (Reagents & Kits, Instruments), Targeted Disease (CNS Diseases, Gastrointestinal Diseases, Oncology, Infectious Diseases, Others), Application (Personalized Medicine, Genetic Screening, Therapeutic, Drug & Biomarker Discovery, Disease Diagnosis Research, Others), Research Type (Outsourced, In-House), End-User (Pharmaceutical & Biotechnology, Academic Centers & Research Institutes, CROs, Others), Laboratory Type (Dry Lab, Wet Lab)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
CosmosID (India), Charles River Laboratories(U.S.), Diversigen (U.S.), Illumina, Inc.(U.S.), Metabiomics Corp.(U.S.), Oxford Nanopore Technologies(U.K.), BaseClear B.V. (Netherlands), BGI (India), BioMathematica (U.S.), Microbiome Therapeutics Innovation Group (U.S.), Clinical-Microbiomics A/S (Denmark), Eurofins Scientific (Luxembourg), LABCYTE INC.(U.S.), Leucine Rich Bio Pvt Ltd.(India), Microbiome Insights(Canada), Zymo Research Corporation (U.S.), Thermo Fisher Scientific Inc.(U.S.), Molzym GmbH & Co. KG (Germany), Norgen Biotek Corp. (Canada), and Phase Genomics Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Microbiome sequencing is defined as a research technology which includes the study of microbes and their roles in the maintenance of healthcare as well as prevalence of diseases. This is mainly carried out by sampling out the human blood, stool and skin. These samples are used for tests that are tried in the labour-intensive techniques of microbiology studies wherein they can isolate the organisms in these samples through the help of genotypic or phenotypic analysis.
Global Microbiome Sequencing Market Dynamics
Drivers
- Rising Prevalence of Chronic Diseases
The microbiome is increasingly linked to various chronic diseases, including obesity, diabetes, inflammatory bowel disease, and cancer. This connection has driven research into microbiome-based diagnostics, therapies, and interventions, further boosting the demand for microbiome sequencing.
- Personalized Medicine
The microbiome's role in personalized medicine is gaining traction. Understanding an individual's microbiome can help tailor treatments and therapies to their specific needs, potentially improving treatment outcomes and reducing side effects. This has led to increased interest in microbiome sequencing for personalized healthcare.
- Expanding Application Areas
Microbiome sequencing is not limited to human health. It is also widely used in agriculture, environmental science, and industrial applications. The expanding range of applications has broadened the market's scope and potential customer base.
Opportunities
- Strategic Collaborations and Partnerships
Many companies and research institutions are forming collaborations and partnerships to accelerate microbiome research and develop innovative products and services. These collaborations help drive innovation and expand market reach
-
Increasing Research Interest
Growing interest and awareness in the role of the human microbiome in health and disease have spurred extensive research efforts. Scientists and researchers are conducting microbiome studies to understand its impact on various aspects of human health, leading to increased demand for microbiome sequencing services and technologies.
Restraints/Challenges
- High Cost of Sequencing
Microbiome sequencing can be expensive, particularly when using advanced sequencing technologies. The cost of equipment, reagents, and data analysis can be a significant barrier for researchers and healthcare institutions, limiting their ability to conduct large-scale studies.
-
Data Analysis Challenges
The massive amount of data generated by microbiome sequencing requires sophisticated bioinformatics tools and expertise for analysis. Many researchers and clinicians may lack the necessary computational skills, leading to data analysis bottlenecks.
This global microbiome sequencing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global microbiome sequencing market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In June 2023, Zymo Research, announced that it has officially launched its Full-Length 16S Sequencing Service, offering researchers high-quality, full-length 16S rRNA gene sequencing for microbiome analysis
- In July 2022, OraSure Technologies launches new product for microbiome researchers to study DNA and RNA
Global Microbiome Sequencing Market Scope
The global microbiome sequencing market is segmented on the basis of sequencing technology, component, targeted disease, application, research type, end-user and laboratory type. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Sequencing Technology
- High-Throughput Sequencing
- Sanger Sequencing
- SBL
- RNA Sequencing
- SBS
- Third-Generation Sequencing
- Whole Genome Sequencing
- Targeted Gene Sequencing
- Shotgun Sequencing
- Others
Component
- Reagents & Kits
- Instruments
Targeted Disease
- CNS Diseases
- Gastrointestinal Diseases
- Oncology
- Infectious Diseases
- Others
Application
- Personalized Medicine
- Genetic Screening
- Therapeutic
- Drug & Biomarker Discovery
- Disease Diagnosis Research
- Others
Research Type
- Outsourced
- In-House
End-User
- Pharmaceutical & Biotechnology
- Academic Centers & Research Institutes
- CROs
- Others
Laboratory Type
- Dry Lab
- Wet Lab
Global Microbiome Sequencing Market Analysis/Insights
The global microbiome sequencing market is analysed and market size insights and trends are provided by country, sequencing technology, component, targeted disease, application, research type, end-user and laboratory type as referenced above.
The countries covered in the global microbiome sequencing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the global microbiome sequencing market because of the strong base of healthcare facilities, strong presence of major players in the market, and rising number of research activities in this region.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, rise in healthcare facilities, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Microbiome Sequencing Market Share Analysis
The global microbiome sequencing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global microbiome sequencing market.
Some of the major players operating in the global microbiome sequencing market are:
- CosmosID (India)
- Charles River Laboratories(U.S.)
- Diversigen (U.S.)
- Illumina, Inc.(U.S.)
- Metabiomics Corp.(U.S.)
- Oxford Nanopore Technologies(U.K.)
- BaseClear B.V. (Netherlands
- BGI (India)
- BioMathematica (U.S.)
- Microbiome Therapeutics Innovation Group (U.S.)
- Clinical-Microbiomics A/S (Denmark)
- Eurofins Scientific (Luxembourg)
- LABCYTE INC.(U.S.)
- Leucine Rich Bio Pvt Ltd.(India)
- Microbiome Insights(Canada)
- Zymo Research Corporation (U.S.)
- Thermo Fisher Scientific Inc.(U.S.)
- Molzym GmbH & Co. KG (Germany)
- Norgen Biotek Corp. (Canada)
- Phase Genomics Inc. (U.S.)
SKU-